ROLE OF ANGIOTENSIN SYSTEM INHIBITION IN THE CARDIOVASCULAR MANIFESTATIONS OF COVID – 19

Abstract

The Association of the drugs inhibiting the angiotensin system with the severity of coronavirus disease has been studied intensively at different research centers of the world over the past year. It has been found that the admitted COVID-19 patients with co-existing cardiovascular diseases taking angiotensinconverting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) develop less severe disease, and persistent ACEI /ARB therapy during their hospitalization lowers the risk of fatality as well. The current literature supports the use of ACEI/ARB therapy for corona patients with comorbidities as it yields better clinical outcomes